Novavax’s South African Phase IIb COVID-19 vaccine trial likely to reveal results within next fortnight, source says

Novavax’s COVID-19 vaccine NVX-CoV2373
NVX-CoV2373 is a two-dose protein subunit vaccine with the second shot administered after 21 days. Credit: Cindy Shebley